Current Multidisciplinary Lymphoma and Myeloma Management for Surgeons
Surg Oncol Clin N Am. 2024 Apr;33(2):447-466. doi: 10.1016/j.soc.2023.12.009. Epub 2024 Jan 27.ABSTRACTAlthough there are more than 100 clinically distinct lymphoid neoplasms with varied prognoses and treatment approaches, they generally share high sensitivity to glucocorticoids, cytotoxic chemotherapy, and radiation. The disease control rates for lymphoid malignancies are higher than many solid tumors, and many are curable even when presenting with extensive involvement. Novel targeted therapies have improved disease control and cure rates for nearly all subtypes of lymphoid neoplasms. Surgical oncologists will primarily ...
Source: Clinical Lymphoma and Myeloma - February 24, 2024 Category: Cancer & Oncology Authors: William B Pearse Erin G Reid Source Type: research
Exploring the Therapeutic Potential of < em > Ganoderma lucidum < /em > in Cancer
J Clin Med. 2024 Feb 18;13(4):1153. doi: 10.3390/jcm13041153.ABSTRACTTriterpenoids, such as ganoderic acid, and polysaccharides, including β-D-glucans, α-D-glucans, and α-D-mannans, are the main secondary metabolites of the medicinal fungus Ganoderma lucidum. There is evidence of the effects of ganoderic acid in hematological malignancies, whose mechanisms involve the stimulation of immune response, the macrophage-like differentiation, the activation of MAP-K pathway, an IL3-dependent cytotoxic action, the induction of cytoprotective autophagy, and the induction of apoptosis. In fact, this compound has been tested in tw...
Source: Clinical Lymphoma and Myeloma - February 24, 2024 Category: Cancer & Oncology Authors: Gabriella Cancemi Santino Caserta Sebastiano Gangemi Giovanni Pioggia Alessandro Allegra Source Type: research
Current Multidisciplinary Lymphoma and Myeloma Management for Surgeons
Surg Oncol Clin N Am. 2024 Apr;33(2):447-466. doi: 10.1016/j.soc.2023.12.009. Epub 2024 Jan 27.ABSTRACTAlthough there are more than 100 clinically distinct lymphoid neoplasms with varied prognoses and treatment approaches, they generally share high sensitivity to glucocorticoids, cytotoxic chemotherapy, and radiation. The disease control rates for lymphoid malignancies are higher than many solid tumors, and many are curable even when presenting with extensive involvement. Novel targeted therapies have improved disease control and cure rates for nearly all subtypes of lymphoid neoplasms. Surgical oncologists will primarily ...
Source: Clinical Lymphoma and Myeloma - February 24, 2024 Category: Cancer & Oncology Authors: William B Pearse Erin G Reid Source Type: research
Laboratory reflex testing strategy for the early identification of primary care patients with multiple myeloma
CONCLUSIONS: The above laboratory interventions agreed with clinicians, making use of laboratory technology resulted in early identification of MM.PMID:38387751 | DOI:10.1016/j.clinbiochem.2024.110730 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - February 22, 2024 Category: Cancer & Oncology Authors: Maria Salinas Emilio Flores Alvaro Blasco Maite Lopez-Garrig ós Ruth Torreblanca Mar ía Leiva-Salinas Irene Gutierrez Carlos Leiva-Salinas PRIMary Care-LABoratory (PRIMLAB) working group Source Type: research
Laboratory reflex testing strategy for the early identification of primary care patients with multiple myeloma
CONCLUSIONS: The above laboratory interventions agreed with clinicians, making use of laboratory technology resulted in early identification of MM.PMID:38387751 | DOI:10.1016/j.clinbiochem.2024.110730 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - February 22, 2024 Category: Cancer & Oncology Authors: Maria Salinas Emilio Flores Alvaro Blasco Maite Lopez-Garrig ós Ruth Torreblanca Mar ía Leiva-Salinas Irene Gutierrez Carlos Leiva-Salinas PRIMary Care-LABoratory (PRIMLAB) working group Source Type: research
Venetoclax and Cobimetinib in Relapsed/Refractory AML: A Phase 1b Trial
CONCLUSION: Venetoclax-cobimetinib showed limited preliminary efficacy similar to single-agent venetoclax, but with added toxicity. Our findings will inform future trials of BCL-2/MAPK pathway inhibitor combinations.PMID:38378362 | DOI:10.1016/j.clml.2024.01.007 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - February 20, 2024 Category: Cancer & Oncology Authors: Marina Y Konopleva Monique Dail Naval G Daver Jacqueline S Garcia Brian A Jonas Karen W L Yee Kevin R Kelly Norbert Vey Sarit Assouline Gail J Roboz Stefania Paolini Daniel A Pollyea Agostino Tafuri Joseph M Brandwein Arnaud Pigneux Bayard L Powell Pierre Source Type: research
Venetoclax and Cobimetinib in Relapsed/Refractory AML: A Phase 1b Trial
CONCLUSION: Venetoclax-cobimetinib showed limited preliminary efficacy similar to single-agent venetoclax, but with added toxicity. Our findings will inform future trials of BCL-2/MAPK pathway inhibitor combinations.PMID:38378362 | DOI:10.1016/j.clml.2024.01.007 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - February 20, 2024 Category: Cancer & Oncology Authors: Marina Y Konopleva Monique Dail Naval G Daver Jacqueline S Garcia Brian A Jonas Karen W L Yee Kevin R Kelly Norbert Vey Sarit Assouline Gail J Roboz Stefania Paolini Daniel A Pollyea Agostino Tafuri Joseph M Brandwein Arnaud Pigneux Bayard L Powell Pierre Source Type: research
The Italian Multicentric Randomized OPTkIMA Trial on Fixed vs Progressive Intermittent TKI Therapy in CML Elderly Patients: 3-Years of Molecular Response and Quality of Life Monitoring After Completing the Treatment Plan
CONCLUSIONS: The intensification of intermittent TKI therapy is associated with a higher incidence of MR3.0 loss, but those patients who maintain the MR3.0 molecular response at the end of the study have been frequently considered eligible for TFR. The HRQoL generally improved during the de-escalation therapy in both randomization arms.PMID:38369436 | DOI:10.1016/j.clml.2024.01.008 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - February 18, 2024 Category: Cancer & Oncology Authors: Michele Malagola Alessandra Iurlo Cristina Bucelli Elisabetta Abruzzese Massimiliano Bonifacio Fabio Stagno Gianni Binotto Marienlla D'Adda Monia Lunghi Monica Crugnola Maria Luisa Ferrari Francesca Lunghi Fausto Castagnetti Gianantonio Rosti Roberto Mass Source Type: research
Optimizing the CAR T-Cell Therapy Experience in Multiple Myeloma: Clinical Pearls From an Expert Roundtable
Clin Lymphoma Myeloma Leuk. 2024 Feb 1:S2152-2650(24)00058-2. doi: 10.1016/j.clml.2024.01.014. Online ahead of print.ABSTRACTChimeric antigen receptor T-cell (CAR-T) therapies offer substantial advancement in the treatment of multiple myeloma (MM). However, the CAR-T therapy process involves complex decision-making that is informed by many variables. This review aims to provide an overview of the patient selection and administration process for CAR-T therapy for MM from the perspective of experienced healthcare providers (HCPs), including considerations for each step in the CAR-T therapy process. Referring HCPs should init...
Source: Clinical Lymphoma and Myeloma - February 18, 2024 Category: Cancer & Oncology Authors: Sikander Ailawadhi Leyla Shune Sandy W Wong Yi Lin Krina Patel Sundar Jagannath Source Type: research
The Italian Multicentric Randomized OPTkIMA Trial on Fixed vs Progressive Intermittent TKI Therapy in CML Elderly Patients: 3-Years of Molecular Response and Quality of Life Monitoring After Completing the Treatment Plan
CONCLUSIONS: The intensification of intermittent TKI therapy is associated with a higher incidence of MR3.0 loss, but those patients who maintain the MR3.0 molecular response at the end of the study have been frequently considered eligible for TFR. The HRQoL generally improved during the de-escalation therapy in both randomization arms.PMID:38369436 | DOI:10.1016/j.clml.2024.01.008 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - February 18, 2024 Category: Cancer & Oncology Authors: Michele Malagola Alessandra Iurlo Cristina Bucelli Elisabetta Abruzzese Massimiliano Bonifacio Fabio Stagno Gianni Binotto Marienlla D'Adda Monia Lunghi Monica Crugnola Maria Luisa Ferrari Francesca Lunghi Fausto Castagnetti Gianantonio Rosti Roberto Mass Source Type: research
Optimizing the CAR T-Cell Therapy Experience in Multiple Myeloma: Clinical Pearls From an Expert Roundtable
Clin Lymphoma Myeloma Leuk. 2024 Feb 1:S2152-2650(24)00058-2. doi: 10.1016/j.clml.2024.01.014. Online ahead of print.ABSTRACTChimeric antigen receptor T-cell (CAR-T) therapies offer substantial advancement in the treatment of multiple myeloma (MM). However, the CAR-T therapy process involves complex decision-making that is informed by many variables. This review aims to provide an overview of the patient selection and administration process for CAR-T therapy for MM from the perspective of experienced healthcare providers (HCPs), including considerations for each step in the CAR-T therapy process. Referring HCPs should init...
Source: Clinical Lymphoma and Myeloma - February 18, 2024 Category: Cancer & Oncology Authors: Sikander Ailawadhi Leyla Shune Sandy W Wong Yi Lin Krina Patel Sundar Jagannath Source Type: research
The Italian Multicentric Randomized OPTkIMA Trial on Fixed vs Progressive Intermittent TKI Therapy in CML Elderly Patients: 3-Years of Molecular Response and Quality of Life Monitoring After Completing the Treatment Plan
CONCLUSIONS: The intensification of intermittent TKI therapy is associated with a higher incidence of MR3.0 loss, but those patients who maintain the MR3.0 molecular response at the end of the study have been frequently considered eligible for TFR. The HRQoL generally improved during the de-escalation therapy in both randomization arms.PMID:38369436 | DOI:10.1016/j.clml.2024.01.008 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - February 18, 2024 Category: Cancer & Oncology Authors: Michele Malagola Alessandra Iurlo Cristina Bucelli Elisabetta Abruzzese Massimiliano Bonifacio Fabio Stagno Gianni Binotto Marienlla D'Adda Monia Lunghi Monica Crugnola Maria Luisa Ferrari Francesca Lunghi Fausto Castagnetti Gianantonio Rosti Roberto Mass Source Type: research
Optimizing the CAR T-Cell Therapy Experience in Multiple Myeloma: Clinical Pearls From an Expert Roundtable
Clin Lymphoma Myeloma Leuk. 2024 Feb 1:S2152-2650(24)00058-2. doi: 10.1016/j.clml.2024.01.014. Online ahead of print.ABSTRACTChimeric antigen receptor T-cell (CAR-T) therapies offer substantial advancement in the treatment of multiple myeloma (MM). However, the CAR-T therapy process involves complex decision-making that is informed by many variables. This review aims to provide an overview of the patient selection and administration process for CAR-T therapy for MM from the perspective of experienced healthcare providers (HCPs), including considerations for each step in the CAR-T therapy process. Referring HCPs should init...
Source: Clinical Lymphoma and Myeloma - February 18, 2024 Category: Cancer & Oncology Authors: Sikander Ailawadhi Leyla Shune Sandy W Wong Yi Lin Krina Patel Sundar Jagannath Source Type: research
A Comparison of 3-Year Follow-up of ZUMA-5 (Axicabtagene Ciloleucel) With SCHOLAR-5 in Relapsed/Refractory Follicular Lymphoma
Clin Lymphoma Myeloma Leuk. 2024 Jan 24:S2152-2650(24)00055-7. doi: 10.1016/j.clml.2024.01.011. Online ahead of print.ABSTRACTIn the pivotal ZUMA-5 trial, axicabtagene ciloleucel (axi-cel; an autologous anti-CD19 chimeric antigen receptor T-cell therapy) demonstrated high rates of durable response in relapsed/refractory follicular lymphoma patients. SCHOLAR-5 is an external control cohort designed to act as a comparator to ZUMA-5. Here, we present an updated comparative analysis of ZUMA-5 and SCHOLAR-5, using the 36-month follow-up data and the intent-to-treat population of ZUMA-5. Using propensity-score methods, 127 patie...
Source: Clinical Lymphoma and Myeloma - February 16, 2024 Category: Cancer & Oncology Authors: Paola Ghione M Lia Palomba Markqayne D Ray Eve H Limbrick-Oldfield Jessica Owen Steve Kanters Sabela Bobillo Maria Teresa Ribiero Caron A Jacobson Sattva S Neelapu Herve Ghesquieres Myrna Nahas Sara Beygi Anik R Patel John G Gribben Source Type: research
A Comparison of 3-Year Follow-up of ZUMA-5 (Axicabtagene Ciloleucel) With SCHOLAR-5 in Relapsed/Refractory Follicular Lymphoma
Clin Lymphoma Myeloma Leuk. 2024 Jan 24:S2152-2650(24)00055-7. doi: 10.1016/j.clml.2024.01.011. Online ahead of print.ABSTRACTIn the pivotal ZUMA-5 trial, axicabtagene ciloleucel (axi-cel; an autologous anti-CD19 chimeric antigen receptor T-cell therapy) demonstrated high rates of durable response in relapsed/refractory follicular lymphoma patients. SCHOLAR-5 is an external control cohort designed to act as a comparator to ZUMA-5. Here, we present an updated comparative analysis of ZUMA-5 and SCHOLAR-5, using the 36-month follow-up data and the intent-to-treat population of ZUMA-5. Using propensity-score methods, 127 patie...
Source: Clinical Lymphoma and Myeloma - February 16, 2024 Category: Cancer & Oncology Authors: Paola Ghione M Lia Palomba Markqayne D Ray Eve H Limbrick-Oldfield Jessica Owen Steve Kanters Sabela Bobillo Maria Teresa Ribiero Caron A Jacobson Sattva S Neelapu Herve Ghesquieres Myrna Nahas Sara Beygi Anik R Patel John G Gribben Source Type: research
